This trial is studying a potential new treatment for people with a specific type of mutation that causes elevated levels of methylmalonic acid. The goal is to assess safety, how the body processes the treatment, and how well it works.
- Methylmalonic Acidemia
1 Primary · 8 Secondary · Reporting Duration: 0 (predose) to 336 hours postdose
1 Treatment Group
1 of 1
33 Total Participants · 1 Treatment Group
Primary Treatment: mRNA-3705 · No Placebo Group · Phase 1 & 2
Who is running the clinical trial?
Age Any Age · All Participants · 5 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
Frequently Asked Questions
What is the highest capacity of participants involved in this clinical trial?
"Indeed, the information accessible on clinicaltrials.gov confirms that this research is actively seeking candidates to join. It was initially announced on August 6th 2021 and has recently been updated on June 16th 2022. The study requires 33 participants from two locations in order to continue." - Anonymous Online Contributor
What other explorations have been made regarding the efficacy of mRNA-3705?
"Currently, mRNA-3705 is the subject of 1 active clinical trial. This experiment has yet to reach Phase 3, though there are 4 sites across Toronto conducting research into this medicine's efficacy." - Anonymous Online Contributor
Is this experiment currently taking on new participants?
"Indeed, the clinicaltrials.gov confirms that this medical study is actively recruiting and has been since August 6th 2021. 33 potential participants are sought between 2 different sites, and the research was last adjusted on June 16th 2022." - Anonymous Online Contributor
Is this a groundbreaking research endeavor?
"Since 2021, mRNA-3705 has been under scientific evaluation. The initial investigation was conducted and funded by ModernaTX, Inc., with 33 participants in the trial cohort. Subsequently, the drug successfully completed Phases 1 & 2 of approval process. Currently there is one ongoing study sponsored by ModernaTX, Inc.." - Anonymous Online Contributor